Drotrecogin alfa (activated) in sepsis: Initial experience with patient selection, cost, and clinical outcomes.

Authors

Thomas Higgins MD, Baystate HealthFollow
Jay Steingrub MD, Baystate HealthFollow
Mark Tidswell MD, Baystate HealthFollow
William McGee MD, Baystate HealthFollow
Gary Tereso, Baystate HealthFollow

Author Department

Emergency Medicine; Medicine

Document Type

Article, Peer-reviewed

Publication Date

11-1-2005

Abstract

During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated for sepsis in a 24-bed medical-surgical intensive care unit. Drotrecogin alfa, activated was administered 46 times to 44 patients (3% of all intensive care u

Publication ISSN

0195-9131

Recommended Citation

J Intensive Care Med. 2005 Nov-Dec;20(6):339-45.